Press Releases

Press Releases

The information contained in press releases should be considered accurate only as of the date of the press release. We disclaim any obligation to supplement or update the information in these press releases.


05 May, 2020

Incyte Reports 2020 First Quarter Financial Results and Provides Updates on Key Clinical Programs

29 April, 2020

Incyte to Present at Upcoming Investor Conference

24 April, 2020

Incyte Appoints Christine Lennon as General Manager, Incyte Biosciences Canada

22 April, 2020

Incyte Announces Pivotal REACH2 Study Data Published in NEJM Highlight Superior Efficacy of Ruxolitinib (Jakafi®) versus Best Available Therapy in Patients with Acute Graft-Versus-Host Disease

17 April, 2020

FDA Approves Incyte’s Pemazyre™ (pemigatinib) as First Targeted Treatment for Adults with Previously Treated, Unresectable Locally Advanced or Metastatic Cholangiocarcinoma

17 April, 2020

Incyte Announces Initiation of Phase 3 RUXCOVID Study Evaluating Ruxolitinib (Jakafi®) as a Treatment for Patients with COVID-19 Associated Cytokine Storm

16 April, 2020

Incyte to Report First Quarter Financial Results

05 April, 2020

Incyte Announces First Presentation of Phase 3 Data from the TRuE-AD Program of Ruxolitinib Cream at the Revolutionizing Atopic Dermatitis Virtual Symposium

02 April, 2020

Incyte Announces Plans to Initiate a Phase 3 Clinical Trial of Ruxolitinib (Jakafi®) as a Treatment for Patients with COVID-19 Associated Cytokine Storm

26 March, 2020

Incyte Names New Member to Its Board of Directors


For Media Inquiries

Catalina Loveman
Executive Director, Public Affairs

+1 302.498.6171 |

For Investor Relations

Michael Booth, D.Phil.
Divisional VP of Investor Relations and Corporate Responsibility

Phone: 302.498.5914


Lauren Ayala, MBA
Senior Director, Investor Relations & Corporate Responsibility

Phone: 302.498.6141


Christine Chiou
Senior Director, Investor Relations

Phone: 302.274.4773